Feature | Published:

Hybritech: Portrait of a Monoclonal Specialist

Bio/Technology volume 1, pages 156161 (1983) | Download Citation


Commercialization of monoclonal antibodies may be the biotechnology success story of the 1980s. While most products of genetic engineering are still characterized as having potential or hypothetical commercial applications, there are at least 30 monoclonal antibody-based products on the market now. Hybritech, a California biotechnology firm, leads the field in production and marketing of new applications for monoclonal antibodies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history





  1. Search for Lawrence Prescott in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing